
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics Inc has established a robust scientific foundation that positions it competitively within the evolving biotech landscape, particularly through its innovative integrin-targeted therapies. The positive Phase I results for its lead candidate, PLN-101095, specifically the substantial increase in IFN-γ among responders and its well-tolerated profile, bolster the prospects for further development and market entry. Furthermore, the experienced management team adeptly handles regulatory interactions, driving confidence that potential commercial risks are mitigated by their track record in successful product launches.
Bears say
Pliant Therapeutics Inc. faces significant challenges associated with the inherent risks in clinical development, particularly regarding potential failures in its lead product candidate, PLN-101095, which targets integrins for solid tumors. The historical difficulties encountered in developing integrin inhibitors for conditions such as idiopathic pulmonary fibrosis (IPF) heighten concerns about the likelihood of clinical setbacks that could jeopardize the company's drug pipeline. Additionally, the company is subject to regulatory uncertainties that could impact its development processes, exacerbating the risks associated with its financial outlook due to a diminished cash position and increased share counts.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares